Immatics and Bristol Myers Squibb Expand Alliance to Develop Cell Therapy Programmes

By Swati Sharan

Pharma Deals Review: Vol 2022 Issue 6 (Table of Contents)

Published: 22 Jun-2022

DOI: 10.3833/pdr.v2022.i6.2698     ISSN: 1756-7874

Section: Licensing



Immatics and Bristol Myers Squibb (BMS) have expanded their strategic partnership to develop multiple allogeneic TCR-T and/or CAR-T programmes...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details